search button

Oxymatrine reverses 5‑fluorouracil resistance by inhibition of colon cancer cell epithelial‑mesenchymal transition and NF‑κB signaling in vitro

  • Authors:
    • Li Liang
    • Jun Wu
    • Jie Luo
    • Li Wang
    • Zu Xuan Chen
    • Cheng Long Han
    • Ting Qing Gan
    • Jie An Huang
    • Zheng Wen Cai

  • View Affiliations

  • Published online on: November 13, 2019     https://doi.org/10.3892/ol.2019.11090
  • Pages: 519-526
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study investigated the sensitization of 5‑fluorouracil (5‑FU)‑resistant colon cancer cells in vitro, using oxymatrine, a Chinese herb, and a quinolizidine alkaloid compound extracted from the root of Sophora flavescens. The HCT‑8 colon cancer cell line and its 5‑FU‑resistant subline HCT‑8/5‑FU were treated with 5‑FU and oxymatrine, alone or in combination, at various doses. The cells were subsequently assessed for changes in cell viability, apoptosis and morphology and analyzed by fluorescence microscopy and western blotting. The data demonstrated that HCT‑8/5‑FU markedly increased the dose of 5‑FU required for the suppression of tumor cell viability (78.77±1.90 µg/ml vs. 9.20±0.96 µg/ml in parental HCT‑8 cells), whereas HCT‑8/5‑FU induced the tumor cell epithelial‑mesenchymal transition (EMT). By contrast, oxymatrine alone and in combination with 5‑FU altered HCT‑8/5‑FU cell morphology, apoptosis and EMT phenotypes. The combination of oxymatrine and 5‑FU reduced the protein expression of snail family transcriptional repressor 2 and vimentin, phosphorylated p65 and induced the expression of E‑cadherin, by inhibiting the nuclear factor κB (NF‑κB) signaling pathway. In conclusion, the data from the present study demonstrated that EMT was associated with 5‑FU chemoresistance in HCT‑8/5‑FU colon cancer cells, and that oxymatrine treatment was able to reverse such resistance. Oxymatrine may regulate tumor cell EMT and inactivate the NF‑κB signaling pathway, and may therefore serve as a potential therapeutic drug to reverse 5‑FU resistance in colon cancer cells.
View Figures
View References

Related Articles

Journal Cover

January-2020
Volume 19 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Liang L, Wu J, Luo J, Wang L, Chen ZX, Han CL, Gan TQ, Huang JA and Cai ZW: Oxymatrine reverses 5‑fluorouracil resistance by inhibition of colon cancer cell epithelial‑mesenchymal transition and NF‑κB signaling in vitro. Oncol Lett 19: 519-526, 2020.
APA
Liang, L., Wu, J., Luo, J., Wang, L., Chen, Z.X., Han, C.L. ... Cai, Z.W. (2020). Oxymatrine reverses 5‑fluorouracil resistance by inhibition of colon cancer cell epithelial‑mesenchymal transition and NF‑κB signaling in vitro. Oncology Letters, 19, 519-526. https://doi.org/10.3892/ol.2019.11090
MLA
Liang, L., Wu, J., Luo, J., Wang, L., Chen, Z. X., Han, C. L., Gan, T. Q., Huang, J. A., Cai, Z. W."Oxymatrine reverses 5‑fluorouracil resistance by inhibition of colon cancer cell epithelial‑mesenchymal transition and NF‑κB signaling in vitro". Oncology Letters 19.1 (2020): 519-526.
Chicago
Liang, L., Wu, J., Luo, J., Wang, L., Chen, Z. X., Han, C. L., Gan, T. Q., Huang, J. A., Cai, Z. W."Oxymatrine reverses 5‑fluorouracil resistance by inhibition of colon cancer cell epithelial‑mesenchymal transition and NF‑κB signaling in vitro". Oncology Letters 19, no. 1 (2020): 519-526. https://doi.org/10.3892/ol.2019.11090